Novavax Inc. shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
Novavax (NVAX) stock jumps as the company beats with its Q4 2025 revenue and records full-year profitability. Read more here.
Novavax has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties.
Zacks Investment Research on MSN
Novavax (NVAX) upgraded to buy: Here's what you should know
Novavax (NVAX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...
Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...
Novavax (NVAX) ended the recent trading session at $7.25, demonstrating a +1.68% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily gain of ...
WASHINGTON — Stock in Gaithersburg, Maryland-based vaccine maker Novavax plunged 86 percent in early Friday trading after reporting disappointing late-stage clinical trial results for one of its drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results